Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Whole brain radiotherapy combined with tislelizumab and chemotherapy for small cell lung cancer with brain metastasis
ChiCTR2300070273Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in small cell lung cancer (SCLC) and brain metastases, sponsored by Zhejiang Cancer Hospital. Primary endpoint: intracranial objective response rate. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
small cell lung cancer (SCLC)brain metastases
Beyond the preview
Go deeper on ChiCTR2300070273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070273.